Chronic Myeloid Leukemia: Diagnosis, Treatment and Outlook

Chronic myeloid leukemia (CML) is a blood and bone marrow cancer caused by an acquired genetic change in blood-forming cells. Modern targeted therapies allow many people with CML to control the disease for many years while maintaining an active daily life.

Chronic Myeloid Leukemia Overview

Chronic myeloid leukemia, also called CML or chronic myelogenous leukemia, is a cancer of the blood-forming cells in the bone marrow. It leads the body to produce too many abnormal white blood cells. CML is often discovered during a routine blood test before it causes noticeable symptoms, and it can frequently be managed effectively with long-term targeted treatment.

Most cases are linked to an acquired change in the DNA of a bone marrow stem cell. This change creates the BCR::ABL1 gene fusion, usually due to a chromosome rearrangement known as the Philadelphia chromosome. The fusion gene produces an overactive protein that encourages leukemia cells to grow and survive.

CML is not contagious and is not usually inherited from a parent. It is a type of leukemia distinct from other blood cancers, so diagnosis and care should be guided by a hematologist or hematologic oncologist. Understanding the disease phase, laboratory results and treatment response is central to planning care.

Symptoms and Disease Phases

Some people with chronic myeloid leukemia feel well at the time of diagnosis. When symptoms occur, they can be nonspecific and may develop gradually. Possible symptoms include persistent tiredness, reduced exercise tolerance, unexplained weight loss, night sweats, low-grade fever, bone discomfort, or a feeling of fullness under the left ribs caused by an enlarged spleen.

A complete blood count may show a raised white blood cell count, sometimes with changes in platelets or red blood cells. These results do not confirm CML on their own, but they prompt further testing to identify the BCR::ABL1 fusion gene.

CML is described in phases. Most people are diagnosed in the chronic phase, when the disease is generally slower growing and responds well to treatment. Accelerated phase and blast phase are more advanced stages with a higher proportion of immature blood cells and a greater need for urgent, specialized care. Ongoing monitoring aims to identify an inadequate response before progression occurs.

• Fatigue or weakness
• Night sweats or fever without a clear infection
• Unintentional weight loss or reduced appetite
• Fullness or discomfort in the upper left abdomen
• Easy bruising, bleeding, or repeated infections in some cases

Causes and Risk Factors

The key biological feature of CML is the BCR::ABL1 gene fusion. It develops during life in cells that form blood and bone marrow; it is not generally passed through families. The resulting abnormal protein is called a tyrosine kinase, and it continuously sends growth signals to leukemia cells.

In most individuals, there is no identifiable personal action, diet, infection or lifestyle factor that caused CML. Increasing age is associated with a higher likelihood of diagnosis, although CML can occur in adults of different ages. Previous exposure to high-dose ionizing radiation is a recognized risk factor, but it accounts for only a small proportion of cases.

People should avoid blaming themselves for a diagnosis. There is no proven screening test for CML in people without symptoms or blood-count abnormalities. Routine medical care and appropriate assessment of unexplained symptoms or abnormal blood tests can help ensure timely evaluation.

How Chronic Myeloid Leukemia Is Diagnosed

Diagnosis begins with a medical history, physical examination and blood tests. A complete blood count and blood smear can identify abnormal numbers or appearances of white blood cells, platelets and red blood cells. Clinicians may also assess the spleen and ask about symptoms such as fatigue, sweating and early fullness after meals.

The diagnosis is confirmed by demonstrating BCR::ABL1 in blood or bone marrow cells. Tests may include cytogenetic testing, fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) testing. A bone marrow aspiration and biopsy may be recommended at diagnosis to examine blood-forming cells directly and help establish the disease phase.

Quantitative PCR is especially important after diagnosis because it measures the amount of BCR::ABL1 genetic material over time. This provides a sensitive way to track molecular response and guide treatment decisions. Results should be interpreted by the treating team, as timing, laboratory methods and individual circumstances all matter.

Treatment Options and Ongoing Monitoring

For most people with chronic-phase CML, treatment starts with a targeted medicine called a tyrosine kinase inhibitor, or TKI. These medicines block the abnormal BCR::ABL1 protein that drives CML cells. Several TKIs are available, and the most suitable option depends on disease features, other health conditions, potential interactions, Chemotherapy Side Effects: What to Expect and How to Manage" class="ahp-ilk">side effects, pregnancy plans and individual treatment goals.

TKIs are commonly taken by mouth and are intended for long-term use. Regular appointments and blood tests are important, particularly during the first year. PCR monitoring assesses whether BCR::ABL1 levels are falling as expected. If a response is not adequate, a clinician may review adherence, drug interactions, mutation testing, side effects and whether a different treatment is appropriate.

Stem cell transplantation is not the first treatment for most people with chronic-phase CML, but it may be considered for selected patients with resistant disease, progression to advanced phase, or specific treatment challenges. Bone marrow transplantation requires careful assessment because it can offer a potential cure but carries significant short- and long-term risks.

A small group of patients who have achieved a deep, stable molecular response for a sustained period may discuss a supervised attempt to stop TKI therapy. This is called treatment-free remission. It is not appropriate for everyone and requires frequent PCR testing, since treatment may need to be restarted if molecular levels rise.

What Is the Life Expectancy for Someone With Chronic Myeloid Leukemia?

Life expectancy for someone with chronic myeloid leukemia varies according to age, overall health, disease phase at diagnosis, response to treatment and access to regular follow-up. For many people diagnosed in chronic phase and treated effectively with modern TKIs, life expectancy can approach that of people without CML.

This improvement reflects the ability of targeted therapies to control the BCR::ABL1-driven leukemia over the long term. However, no individual prognosis can be determined from a general statistic. A hematology team can provide a more personalized outlook using molecular test results, treatment tolerance and other health factors.

Maintaining regular monitoring and taking treatment exactly as prescribed are important parts of achieving the best possible long-term disease control. Patients should discuss side effects early rather than stopping medication on their own, because alternative treatment strategies may be available.

How Fast Does Chronic Myeloid Leukemia Progress?

Chronic myeloid leukemia often develops slowly, which is why it is called “chronic.” Without treatment, however, it can eventually progress from chronic phase to accelerated phase and then blast phase. The speed of progression is unpredictable and differs between individuals.

With effective TKI treatment and appropriate molecular monitoring, the likelihood of progression is substantially reduced for many patients. A rising BCR::ABL1 level, failure to reach expected response milestones, new chromosome changes or worsening blood counts may signal the need for prompt review by the care team.

Advanced-phase CML behaves more aggressively and requires urgent specialist management. For this reason, missed follow-up visits, new symptoms or difficulty taking prescribed medication should be discussed with the treating clinician as soon as possible.

Survival, Long-Term Living and When to Seek Medical Care

What is the longest someone has lived with CML? There is no single verified maximum length of survival that applies to all people with CML. Some people have lived with the condition for decades, particularly when it is diagnosed in chronic phase and responds well to therapy. Individual experiences vary, and long-term outcome depends on continued monitoring and the person’s overall health.

What is the survival rate for patients with chronic myeloid leukemia (CML)? Survival rates are population estimates rather than predictions for an individual. Outcomes have improved greatly since targeted therapies became available, especially for people diagnosed in chronic phase. A clinician can explain the most relevant current data in the context of a patient’s age, disease phase, treatment response and local reporting methods.

When to seek medical care: A person should arrange medical assessment for ongoing unexplained fatigue, drenching night sweats, unintentional weight loss, persistent fever, unusual bruising or bleeding, or abdominal fullness. Anyone already diagnosed with CML should contact their care team promptly for fever, signs of infection, significant bleeding, shortness of breath, severe new pain, rapidly worsening fatigue, or troublesome treatment side effects.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals provide diagnostic assessment and treatment planning for international patients with CML. Care should remain individualized, with follow-up coordinated closely between the patient and qualified hematology professionals.

Frequently asked questions